Research publications





A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines, Goksøyr et al., Vaccines (2023)

First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2, Smit et al., The Lancet Microbe (2023)


Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine, Ruzzi et al., Biomedicines (2022)

FAS2FURIOUS: Moderate-Throughput Secreted Expression of Difficult Recombinant Proteins in Drosophila S2 Cells, Coker et al., Front. Bioengineering and Biotechnology (2022)

Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies, Ko et al., Nature Communications (2022)

A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques, Volkmann et al., Front. Immunol. (2022)

Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers, Prentoe J et al., npj Vaccines (2022)


Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination, Minassian et al., Med. (2021)

Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors, Nielsen et al., Cell Reports Medicine (2021)

Site-Specific O-Glycosylation Analysis of SARS-CoV-2 Spike Protein Produced in Insect and Human Cells, Bagdonaite, I. et al., Viruses (2021)

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity, Fougeroux C. et al.Nat Commun (2021)


Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes, Healer J, et al., Cell Microbiol (2019)

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria, Mordmüller B, et al., Clin Infect Dis (2019)

Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies, Alanine et al., Cell (2019)

Structure of Plasmodium falciparum Rh5-CyRPA-Ripr invasion complex, Wong W, et al., Nature (2019)


Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody, Lennartz F, et al., Nat Commun (2018)

Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells, Jin J, et al., NPJ Vaccines (2018)

Virus-like particle display of HER2 induces potent anti-cancer responses, Palladini A, et al., Oncoimmunology (2018)


Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal ‘C-tag’, Jin et al., International Journal for Parasitology (2017)

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions, Payne et al., JCI insight (2017)


Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system, Hjerrild KA, et al., Sci Rep (2016)

Bacterial superglue enables easy development of efficient virus-like particle based vaccines, Thrane S, et al., J Nanobiotechnology (2016)


The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine, Nielsen MA, et al., PLoS One (2015)

A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA, Thrane et al., PLOS One (2015)


Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies, Wright KE, et al., Nature (2014)